Latest News & Features
Pharma
Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use. 17 September 2026
Regulation & Industry
Featuring interviews with dozens of lawyers, LSIPR published a five-part deep dive into the levers driving a surge in life sciences dealmaking. Author Marisa Woutersen discovered where buyers are placing their bets, what sellers can do to make themselves 'acquisition-ready', and why IP can make or break a deal. 17 September 2026
Biotech
BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market. 16 September 2026
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa. 16 September 2026
Biotech
Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational. 15 September 2026
Careers
The firm has strengthened its intellectual property, capital markets, corporate, transactional and litigation capabilities with the addition of the group, which will be based across California and Texas. 15 September 2026
Regulation & Industry
Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms. 14 September 2026
Regulation & Industry
For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking. 11 September 2026
Regulation & Industry
UPC judges and practitioners from firms including Freshfields, Kather Augenstein, EIP, Simmons & Simmons and Brinkhof converged at CIPA’s annual conference to offer candid views on the court’s biggest pressure points, from overloaded German divisions to harmonisation and cross-court influence. 10 September 2026
Careers
The senior lawyer previously led Johnson & Johnson’s global pharmaceutical patent team, advising on patent portfolios, R&D, licensing, M&A and litigation. 10 September 2026